收费全文 | 31133篇 |
免费 | 2041篇 |
国内免费 | 158篇 |
耳鼻咽喉 | 268篇 |
儿科学 | 503篇 |
妇产科学 | 309篇 |
基础医学 | 4618篇 |
口腔科学 | 931篇 |
临床医学 | 3029篇 |
内科学 | 7476篇 |
皮肤病学 | 460篇 |
神经病学 | 3503篇 |
特种医学 | 1861篇 |
外科学 | 4191篇 |
综合类 | 177篇 |
一般理论 | 11篇 |
预防医学 | 1289篇 |
眼科学 | 604篇 |
药学 | 1807篇 |
中国医学 | 52篇 |
肿瘤学 | 2243篇 |
2023年 | 250篇 |
2022年 | 361篇 |
2021年 | 826篇 |
2020年 | 514篇 |
2019年 | 714篇 |
2018年 | 798篇 |
2017年 | 617篇 |
2016年 | 880篇 |
2015年 | 998篇 |
2014年 | 1261篇 |
2013年 | 1556篇 |
2012年 | 2527篇 |
2011年 | 2526篇 |
2010年 | 1515篇 |
2009年 | 1359篇 |
2008年 | 2225篇 |
2007年 | 2238篇 |
2006年 | 2162篇 |
2005年 | 2033篇 |
2004年 | 1755篇 |
2003年 | 1673篇 |
2002年 | 1564篇 |
2001年 | 286篇 |
2000年 | 223篇 |
1999年 | 293篇 |
1998年 | 313篇 |
1997年 | 230篇 |
1996年 | 173篇 |
1995年 | 163篇 |
1994年 | 128篇 |
1993年 | 95篇 |
1992年 | 70篇 |
1991年 | 63篇 |
1990年 | 44篇 |
1989年 | 61篇 |
1988年 | 39篇 |
1987年 | 33篇 |
1986年 | 36篇 |
1985年 | 35篇 |
1984年 | 31篇 |
1983年 | 39篇 |
1982年 | 35篇 |
1981年 | 31篇 |
1980年 | 33篇 |
1975年 | 26篇 |
1974年 | 25篇 |
1938年 | 24篇 |
1937年 | 31篇 |
1936年 | 25篇 |
1935年 | 35篇 |
Introduction
Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.Method
A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.Results
The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case.Discussion
The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. 相似文献Areas covered: We report on medication use research and have conducted a systematic review of observational studies on medication use to provide an updated overview on characteristics, objectives, methods, and patterns in hospitalized neonates. Moreover, a review on aspects of medication use for opioids, anti-epileptics, gastric acid-related disorders and respiratory stimulants with emphasis on trends and impact of interventions is presented, illustrating how research on medication use can contribute to improved neonatal pharmacotherapy and more focused research. Medication use reports describe patterns and provide signals on irrational use, benchmarking, or can guide research priorities. Moreover, this may generate information on how neonatal health topics and their pharmacotherapy are handled over time or across regions.
Expert opinion: Research on medicine utilization is relevant, since it will inform us on aspects like trends, variability, or about the impact and pattern of implementation of guidelines in neonates. Further progress necessitates to merge datasets on medication use with clinical characteristics, and perinatal drug use remains an area in need of additional research. 相似文献